Is Wegovy Effective for Weight Loss? What the Evidence Shows

What the clinical trials actually found

The headline number most people encounter is 15%. That comes from STEP 1, published in the New England Journal of Medicine, which followed 1,961 adults with obesity over 68 weeks. Participants taking semaglutide 2.4mg lost an average of around 15% of their starting body weight; those on placebo lost roughly 2.4%. The gap is substantial and consistently replicated across the STEP programme.

Numbers like these tell you about averages. Some participants lost considerably more; others less. The trial population did not include people with type 2 diabetes, who tend to see smaller reductions with GLP-1 medicines generally. If you want to understand how effective semaglutide is across the evidence base, the 15% average is the right starting point, held alongside an honest acknowledgement that individual results vary, and you can then explore how Wegovy's effectiveness translates to real-world weight loss from there.

Since the original approval, Novo Nordisk developed a higher 7.2mg maintenance dose. Trials at that dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide (Mounjaro). The MHRA approved the dedicated single-dose 7.2mg pen in April 2026 for adults with a BMI of 30 or above. Specific dose availability is always confirmed at consultation, because what a prescriber starts you on depends on your circumstances, not on what sounds most impressive in a summary.

What makes some people respond better than others

Effectiveness is not a fixed property of the medicine on its own. Three things shape how much weight a given person loses.

First, adherence. Semaglutide is titrated gradually, starting at 0.25mg and stepping up every four weeks toward 2.4mg (or 7.2mg under the newer schedule). People who stay on the full titration and reach the maintenance dose tend to see better results than those who reduce their dose to manage side effects and never increase again. This is worth knowing upfront: the early weeks can involve nausea and digestive discomfort, which often settles, but some patients stop there rather than continuing through to the therapeutic dose.

Second, lifestyle. The trials combined the injection with a reduced-calorie diet and increased activity. Wegovy works with those changes, not instead of them. The timing and conditions under which Wegovy works best consistently point toward structured lifestyle support alongside the medicine.

Third, individual biology. Starting BMI, metabolic rate, gut hormone response and whether someone has type 2 diabetes all influence outcomes. A prescriber reviewing your health in full gives a more honest picture of expected results than any population average can.

How Wegovy compares and where it sits in the UK landscape

Among the GLP-1 medicines currently licensed in the UK for weight management, Wegovy and Mounjaro (tirzepatide) are the two main options for most adults. In the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4mg in a head-to-head comparison over 72 weeks. The 7.2mg Wegovy dose narrows that gap, though a direct head-to-head at equal maintenance doses has not been conducted. Comparing semaglutide options is worth doing if you are deciding between formulations.

Wegovy is also now available as a daily tablet (approved by the MHRA on 11 June 2026 as the UK's first oral GLP-1 for weight management), which changes the accessibility picture for people who prefer not to inject. Which form of semaglutide suits you, and whether semaglutide or tirzepatide is more appropriate, is a clinical question. Cost is part of that decision too; you can explore how Wegovy is priced in the UK to understand what to expect before consulting.

NICE recommends semaglutide (Wegovy) for use within specialist weight management services, for a maximum of two years, for adults with a BMI of 35 or above (or 30–34.9 meeting specialist referral criteria) and at least one weight-related comorbidity, per NICE technology appraisal TA875. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Private prescribing follows the licensed criteria in the SmPC rather than NHS commissioning thresholds, so the eligibility picture is wider for people accessing treatment outside the NHS.

Making a realistic decision

Asking whether Wegovy is effective is the right question. The honest answer is yes, with meaningful average weight loss shown consistently in well-designed trials, and with a new, higher-dose option now approved. The more useful follow-on question is whether it is likely to be effective for you specifically, given your starting weight, health history, capacity to manage the titration schedule and willingness to pair it with dietary change.

That is the conversation a prescriber has with you before anything is approved or dispensed. At nume, a GPhC-registered prescriber reads your consultation the same day, not a rules engine. Semaglutide's mechanism and what to expect from treatment is worth reading before you start. If you are weighing up whether to proceed, checking your eligibility through a free consultation is a practical first step that costs nothing and commits you to nothing.